XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 712,029 $ 595,275 $ 1,360,862 $ 1,191,690
ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 38,558 40,318 73,820 74,721
Product        
Disaggregation of Revenue [Line Items]        
Revenue 702,129 584,698 1,339,944 1,171,124
Marketed by Company | Products excluding ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 663,571 544,380 1,266,124 1,096,403
Marketed by Company | Products excluding ALDURAZYME | United States        
Disaggregation of Revenue [Line Items]        
Revenue 227,449 191,655 420,448 358,439
Marketed by Company | Products excluding ALDURAZYME | Europe        
Disaggregation of Revenue [Line Items]        
Revenue 220,990 183,434 416,738 344,126
Marketed by Company | Products excluding ALDURAZYME | Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 84,418 75,444 163,012 143,192
Marketed by Company | Products excluding ALDURAZYME | Middle East        
Disaggregation of Revenue [Line Items]        
Revenue 49,701 25,630 106,776 117,272
Marketed by Company | Products excluding ALDURAZYME | Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 81,013 68,217 159,150 133,374
Marketed by Sanofi | ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue $ 38,558 $ 40,318 $ 73,820 $ 74,721